BDSX

$16.59

Pre-MarketAs of Mar 17, 8:00 PM UTC

Biodesix, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$16.59
Potential Upside
5%
Whystock Fair Value$17.42
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identi...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$163.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-383.09%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.61

Recent News

MarketBeat
Mar 13, 2026

Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference

Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays event. Commercially, the company’s primary emphasis is lung disease, while its research, development,

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 6, 2026

Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference

Biodesix (NASDAQ:BDSX) outlined its current commercial focus, growth priorities, and financial milestones during a presentation at the 46th annual TD Cowen Healthcare Conference, where Chief Financial Officer Robin Cowie discussed the company’s positioning in lung nodule management and its biopharma

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 5, 2026

How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target

Biodesix’s latest analyst update trims the fair value estimate from US$35 to US$30, resetting the target level used in the valuation work. Supporters of the new target link it to the recent upgrade to Outperform, 2026 revenue guidance that sits 3% ahead of earlier expectations, and a balance sheet that analysts describe as significantly improved, while skeptics question how durable the recent execution really is. As you read on, you will see how these shifting views can help you track and...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 3, 2026

Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet

The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 3, 2026

Are Medical Stocks Lagging Biodesix (BDSX) This Year?

Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

BEARISH
Negative press. News cycle fixated on risk factors or misses.